213 related articles for article (PubMed ID: 34064158)
1. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
[TBL] [Abstract][Full Text] [Related]
2. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
3. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
5. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
6. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
[TBL] [Abstract][Full Text] [Related]
7. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
Liu D; Xu X; Wen J; Zhang C; Fan M
Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
[TBL] [Abstract][Full Text] [Related]
8. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma of Unknown Primary with
Zhao P; Peng L; Wu W; Zheng Y; Jiang W; Zhang H; Tong Z; Liu L; Ma R; Wang L; Yao M; Wang K; Fang W; Wu L
Oncologist; 2019 Apr; 24(4):449-454. PubMed ID: 30679319
[TBL] [Abstract][Full Text] [Related]
10. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
Matsuda H; Hara M; Iwakami SI; Takahashi K
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906872
[TBL] [Abstract][Full Text] [Related]
11. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Liu L; Hou F; Liu Y; Li W; Zhang H
J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
[TBL] [Abstract][Full Text] [Related]
12. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
13. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
[No Abstract] [Full Text] [Related]
14. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
15. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract][Full Text] [Related]
16. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract][Full Text] [Related]
17. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
18. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract][Full Text] [Related]
19. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
20. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]